LONDON--(BUSINESS WIRE)--Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, notes the publication today of the final phase I data from the first ever ...
LONDON & BASEL, Switzerland--(BUSINESS WIRE)--Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, and Lonza, a global development and manufacturing ...
Allergic diseases represent a major global health burden, placing significant strain on health care systems worldwide. Severe conditions such as anaphylaxis, asthma, food allergy, and allergic ...
Purpose: The pharmacology, efficacy, dosage, adverse events, and economics of omalizumab are discussed. Summary: Omalizumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the Cε3 ...
LONDON – Epsilogen Ltd. has raised £30.8 million (US$41.5 million) in an oversubscribed series B, after its lead immunoglobulin E (IgE) program delivered positive results in a phase I in advanced ...
It is estimated that around 10% of the US population has peanut allergies, a medical emergency that can be treated but not cured. Compared to those without allergies, these individuals are at a ...
Allergic diseases represent a major global health burden, placing significant strain on healthcare systems worldwide. Severe conditions such as anaphylaxis, asthma, food allergy, and allergic rhinitis ...
Many donor kidneys that are transplanted are rejected by the recipient within ten years after transplantation. One reason for this are immunoglobulin G antibodies (IgG), which act against human ...
The best associations among omalizumab dose, suppression of free IgE concentration, and outcome are described in clinical trials involving patients with SAR. In the initial dose-ranging study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results